On March 25, 2026, Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $10.8 million for the year, a significant decline from a net income of $3.6 million in 2024. This shift was primarily attributed to a non-cash impairment charge related to KIO-104, which does not reflect any change in development timelines or strategic focus. The company ended 2025 with $17.1 million in cash and cash equivalents, which it expects will fund operations into late 2027, beyond anticipated data readouts for its ongoing Phase 2 clinical trials, ABACUS-2 and KLARITY.

Kiora has made notable advancements in its clinical pipeline, including the initiation of two active Phase 2 trials for KIO-301 and KIO-104. KIO-301 is being evaluated in patients with advanced retinitis pigmentosa, while KIO-104 is being tested for macular edema due to retinal inflammation. The company has also strengthened its commercial network through an option agreement with Senju Pharmaceutical Co. Ltd. for KIO-301 in key Asian markets, potentially worth up to $110 million plus royalties.

Despite the increased losses, Kiora's leadership remains optimistic about the future. CEO Brian M. Strem highlighted the company's transition from trial preparation to execution, emphasizing the importance of these trials in delivering new treatment options for patients with retinal diseases. The company is actively recruiting and dosing patients in both trials, with initial data readouts expected in the first half of 2027. However, the financial results indicate challenges ahead, particularly in managing operational costs and achieving profitability in the near term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.